Glioblastoma is the most aggressive cancer that begins within the brain. Its symptoms may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. A company out of Toronto, with headquarters in Houston is making progress on fighting the disease.
Medicenna Therapeutics Corp. (TSX:MDNA) has completed a retrospective study on subjects with recurrent Glioblastoma who matched eligibility requirements of subjects enrolled in the MDNA55-05 clinical trial.
This study was conducted to compare the survival of subjects treated with MDNA55, an interleukin-4 receptor (IL4R) targeted therapy, in the Phase 2b rGBM clinical trial versus matched patients (Synthetic Control Arm or SCA) recently treated using other approved therapies.
Said CEO Fahar Merchant, "This first true apples-to-apples comparison of the data shows that a single treatment with MDNA55 has the ability to more than double the survival rates in patients with the most aggressive form of rGBM.
"We hope that these results are a watershed moment in the battle against this aggressive and fatal disease, and are particularly meaningful considering that an even modest improvement in survival of 25% has not been demonstrated by any of the approved treatments of rGBM in more than two decades."
Shares in MDNA climbed 36 cents, or 13.7%, to $2.99, on volume topping 207,000 shares.
